Staff

Functional Brands Inc. and Market Performance Group Forge High-Impact Partnership to Supercharge Growth of Kirkman(R) Brand in the Expanding Health & Wellness Market

Lake Oswego, Oregon--(Newsfile Corp. - November 10, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025

Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025Northvale,...

Trillion-Dollar Digital Healthcare Transformations Shaped by AI, Quantum and Biotech Breakthroughs at GITEX GLOBAL

The world's largest tech and AI show brought groundbreaking innovations in healthcare, neurotech and life sciences to the forefront M42,...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE...

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been...

Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels...

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for...

error: Content is protected !!